FIRST-IN-CLASS EPIGENETIC ONCOLOGY PLATFORM

Targeting Metal-Dependent Epigenetic Dysregulation

Telomir Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer and age-related disease.

Its lead investigational candidate, Telomir-Zn, is designed to restore epigenetic regulation associated with tumor progression, genomic instability, and treatment resistance.